Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-FR Version v4-FR
Language French French
Date Updated 2019-11-05 2019-10-16
Drug Identification Number 02237924 02237924
Brand name AVAPRO AVAPRO
Common or Proper name Avapro Avapro
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients IRBESARTAN IRBESARTAN
Strength(s) 150MG 150MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 90 90
ATC code C09CA C09CA
ATC description ANGIOTENSIN II ANTAGONISTS, PLAIN ANGIOTENSIN II ANTAGONISTS, PLAIN
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2019-10-21 2019-10-21
Actual start date
Estimated end date Unknown 2019-11-15
Actual end date
Shortage status Actual shortage Anticipated shortage
Company comments Increase in demand, supply delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Increase in demand, supply delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments